Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.

Secondary, post hoc analysis of a phase 3a, randomised, double-blind, placebo- and active-controlled trial

“This secondary, post hoc analysis assessed the proportions of participants achieving BMI < 27 kg/m2 and/or WHtR < 0.53 targets, and percentage weight loss by anthropometric target.”

Adults without diabetes with BMI ≥ 30 kg/m2, or ≥ 27 kg/m2 with ≥ 1 obesity-related complication

“The phase 3a, 68‐week REDEFINE 1 trial randomised adults without diabetes with BMI ≥ 30 kg/m2, or ≥ 27 kg/m2 with ≥ 1 obesity‐related complication, to once‐weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention.”

3417 participants randomised to treatment groups

“In the REDEFINE 1 trial, 3417 participants were randomised to CagriSema 2.4 mg/2.4 mg (n = 2108), semaglutide 2.4 mg (n = 302), cagrilintide 2.4 mg (n = 302), or placebo (n = 705), and lifestyle intervention, for 68 weeks (Figure S1) [20].”

68 weeks

“The phase 3a, 68‐week REDEFINE 1 trial randomised adults without diabetes with BMI ≥ 30 kg/m2, or ≥ 27 kg/m2 with ≥ 1 obesity‐related complication, to once‐weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention.”

A greater proportion of participants receiving CagriSema achieved both BMI < 27 kg/m2 and WHtR < 0.53 targets compared to other treatment groups

“The proportion of participants achieving both BMI < 27 kg/m2 and WHtR < 0.53 targets at week 68 was 30.3%, 19.1%, 9.0%, and 3.3% in participants who received CagriSema, semaglutide, cagrilintide, or placebo respectively.”

Participants who achieved anthropometric targets had a higher proportion of maintaining or achieving cardiometabolic outcomes compared to those who did not

“Across all treatment groups, a greater proportion of individuals who achieved BMI and/or WHtR targets reached cardiometabolic outcomes compared with those who did not attain those targets (Figure 3).”

At more stringent cut-off values, anthropometric targets were better measures than percentage weight loss for reaching cardiometabolic outcomes

“At more stringent cut‐off values, anthropometric targets were better measures than percentage weight loss.”

Post hoc nature of the study, reduced capacity for statistical comparisons, patients were not treated-to-target, and the population was predominantly female and White

“Limitations include the post hoc nature of the study, the reduced capacity for statistical comparisons and the fact that patients were not treated‐to‐target.”